News | May 30, 2023
Jubilant Pharmova posts Q4FY23 consolidated loss at Rs. 97.84 Cr
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The company reported lifetime high EBIDTA of Rs. 250 crores
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Medical Device Policy is a progressive step in propelling the country towards Atmanirbharta in the heavily import dependent Medical Device Sector
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
The product is expected to be launched in June 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Product deliveries scheduled in Q3 of 2023
Subscribe To Our Newsletter & Stay Updated
